Physician profile
Pushpalatha Arakere
NPI 1154380343
$10,677.54
in general payments reported to CMS, 2019-2025
23 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $1,025 · 2021: $1,268 · 2022: $1,789 · 2023: $1,840 · 2024: $2,077 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,459 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,459.48 |
| Education | $366.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,475.72 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $1,494.06 | 2019-2025 | Biktarvy, Veklury |
| Insmed, INC. | $1,109.61 | 2019-2025 | Arikayce, Brinsupri |
| Emd Serono, INC. | $872.39 | 2019-2025 | Serostim, Serostim |
| Merck Sharp & Dohme LLC | $764.67 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Astellas Pharma US INC | $751.42 | 2021-2025 | Cresemba |
| Electromed, INC. | $576.95 | 2022-2025 | Smartvest |
| Janssen Biotech, INC. | $516.21 | 2019-2022 | |
| Theratechnologies INC. | $445.62 | 2019-2025 | Egrifta, Trogarzo |
| Paratek Pharmaceuticals, INC. | $353.18 | 2020-2025 | Nuzyra |
| Abbvie INC. | $256.97 | 2021-2024 | |
| La Jolla Pharmaceutical Company | $217.51 | 2021-2025 | Xacduro |
| Philips North America LLC | $171.01 | 2019-2025 | Vest Therapy Und, (8874) Incourage |
| Mayne Pharma Commercial LLC | $153.80 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $127.73 | 2021-2023 | Prezista |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $89.99 | 2019 | |
| Baxter Healthcare | $71.52 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Ferring Pharmaceuticals INC. | $68.67 | 2022-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $42.32 | 2024-2025 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $41.86 | 2020 | |
| Qiagen, LLC | $28.93 | 2025 | |
| Melinta Therapeutics, LLC | $24.39 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $23.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushpalatha Arakere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.